- Home
- AKRO vs VZIO Comparison
AKRO vs VZIO Comparison
Compare AKRO & VZIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- VZIO
- Stock Information
- Founded
- AKRO 2017
- VZIO 2002
- Country
- AKRO United States
- VZIO United States
- Employees
- AKRO N/A
- VZIO N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- VZIO Consumer Electronics/Appliances
- Sector
- AKRO Health Care
- VZIO Consumer Staples
- Exchange
- AKRO Nasdaq
- VZIO Nasdaq
- Market Cap
- AKRO 2.4B
- VZIO 2.3B
- IPO Year
- AKRO 2019
- VZIO 2021
- Fundamental
- Price
- AKRO $28.09
- VZIO $11.28
- Analyst Decision
- AKRO Strong Buy
- VZIO Hold
- Analyst Count
- AKRO 7
- VZIO 8
- Target Price
- AKRO $43.20
- VZIO $11.50
- AVG Volume (30 Days)
- AKRO 617.2K
- VZIO 3.3M
- Earning Date
- AKRO 11-08-2024
- VZIO 11-06-2024
- Dividend Yield
- AKRO N/A
- VZIO N/A
- EPS Growth
- AKRO N/A
- VZIO N/A
- EPS
- AKRO N/A
- VZIO 0.01
- Revenue
- AKRO N/A
- VZIO $1,738,600,000.00
- Revenue This Year
- AKRO N/A
- VZIO $7.80
- Revenue Next Year
- AKRO N/A
- VZIO $9.94
- P/E Ratio
- AKRO N/A
- VZIO $1,267.91
- Revenue Growth
- AKRO N/A
- VZIO 1.62
- 52 Week Low
- AKRO $14.41
- VZIO $6.61
- 52 Week High
- AKRO $37.00
- VZIO $11.37
- Technical
- Relative Strength Index (RSI)
- AKRO 38.58
- VZIO 54.90
- Support Level
- AKRO $31.12
- VZIO $11.05
- Resistance Level
- AKRO $35.11
- VZIO $11.34
- Average True Range (ATR)
- AKRO 1.99
- VZIO 0.10
- MACD
- AKRO -0.53
- VZIO -0.00
- Stochastic Oscillator
- AKRO 11.68
- VZIO 74.60
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About VZIO VIZIO Holding Corp.
VIZIO Holding Corp operates two distinct integrated businesses: Device and Platform+. Through Device business, it offers a range of high-performance Smart TVs designed to address specific consumer preferences, as well as a portfolio of soundbars that deliver immersive audio experiences. It generates revenue from the shipment of these devices to retailers and distributors across the United States, as well as directly to consumers through the website. The Company's reportable segments: Device, and Platform+T. It derives maximum revenue from Device Segment.